NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 420
(Total Views: 216)
Posted On: 09/17/2021 4:03:07 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of proprietary patented drug-delivery platform DehydraTECH(TM), recently released partial results from human clinical study HYPER-H21-1. The study evaluated DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension/high blood pressure. “The partial results showed that blood pressure was reduced across both male and female volunteers; it was more pronounced with DehydraTECH-CBD in the study’s first 10 to 50 minutes. These results reinforced the pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic CBD controls,” reads a recent article. Lexaria was also pleased that the subjects of this human clinical study tolerated the DehydraTECH-CBD, with no serious adverse events or side effects observed or reported. “Chris Bunka, CEO of Lexaria, commented on the study, saying, ‘We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of proprietary patented drug-delivery platform DehydraTECH(TM), recently released partial results from human clinical study HYPER-H21-1. The study evaluated DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension/high blood pressure. “The partial results showed that blood pressure was reduced across both male and female volunteers; it was more pronounced with DehydraTECH-CBD in the study’s first 10 to 50 minutes. These results reinforced the pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic CBD controls,” reads a recent article. Lexaria was also pleased that the subjects of this human clinical study tolerated the DehydraTECH-CBD, with no serious adverse events or side effects observed or reported. “Chris Bunka, CEO of Lexaria, commented on the study, saying, ‘We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼